Larissa Habib, MD
Ophthalmology · Fairfield, CTNPI 1447525654
Payments from drug & device makers
What this record shows
Amgen accounts for 86.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $2,178 and has fallen 82.5% since, to $381 in 2025.
Across 47 payments — averaging $65.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Springworks Therapeutics, Inc.$115
- Axogen$98
- ANI Pharmaceuticals, Inc.$59
- Merz Pharmaceuticals, LLC$48
- Galderma Laboratories, L.p.$38
- plus $66 from 3 others
What the payments were for
- Speaking & faculty fees$1,74057%
- Food & beverage$1,33543%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 31 | $2,652 |
| Springworks Therapeutics, Inc. | 5 | $115 |
| Axogen | 1 | $98 |
| ANI Pharmaceuticals, Inc. | 3 | $59 |
| Merz Pharmaceuticals, LLC | 2 | $48 |
| Galderma Laboratories, L.p. | 2 | $38 |
| Merz North America, Inc. | 1 | $35 |
| Tarsus Pharmaceuticals, Inc. | 1 | $17 |
| Dompe US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,995
How this compares
$3,075 in reported general payments places this provider in the 80th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 241 | $2,230 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 143 | $1,288 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $218 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Fairfield
- Marc WeitzmanFairfield$4K
- Ian GorovoyFairfield$3K
- Jonathan SteinFairfield$3K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Anish ShahNorwich$38K
- Michael KovalFarmington$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.